Comparison of agents that affect aldosterone action

Seminars in Nephrology

Volumn 34, Issue 3, 2014, Pages 285-306

  Tamargo, Juan ^a   Solini, Anna ^b   Ruilope, Luis M ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Aldosterone; Aldosterone receptor antagonists; Aldosterone synthase inhibitors; Canrenone; Eplerenone; Heart failure; Hyperaldosteronism; Hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; BENIDIPINE; BISOPROLOL; CANRENOIC ACID; CILNIDIPINE; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; ENALAPRIL; EPLERENONE; FAB 286A; FINERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LCI 699; LOSARTAN; PF 03882845; PLACEBO; RAMIPRIL; SM 368229; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNCLASSIFIED DRUG; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ALBUMINURIA; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROTIC PLAQUE; BREAST TENDERNESS; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TISSUE LEVEL; ESSENTIAL HYPERTENSION; GLUCOSE HOMEOSTASIS; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; LIBIDO DISORDER; LIVER CIRRHOSIS; LOW DRUG DOSE; MASTALGIA; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYDIPSIA; POLYURIA; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENAL PROTECTION; RESISTANT HYPERTENSION; REVIEW; SEXUAL DYSFUNCTION; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; HYPERALDOSTERONISM; PHYSIOLOGY;

ALDOSTERONE; ANIMALS; EPITHELIAL SODIUM CHANNEL BLOCKERS; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; VENTRICULAR FUNCTION, LEFT;

EID: 84903999244     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.04.005     Document Type: Review

References (177)

1. Funder J.W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009, 53:286-290.
2. Messaoudi S., Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J Suppl 2011, 13:B4-B9.
3. Brown N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013, 9:459-469.
4. Ruilope L. Aldosterone, hypertension, and cardiovascular disease. An endless story. Hypertension 2008, 52:1-2.
5. Zannad F., Gattis Stough W., Rossignol P., et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012, 33:2782-2795.
6. Ibrahim H.N., Hostetter T.H. Aldosterone in renal disease. Curr Opin Nephrol Hypertens 2003, 12:159-164.
7. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
8. Williams J.S., Williams G.H. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003, 88:2364-2372.
9. Messaoudi S., Azibani F., Delcayre C., et al. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012, 350:266-272.
10. Rocha R. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810.
11. Connell J.M., Davies E. The new biology of aldosterone. J Endocrinol 2002, 186:1-20.
12. Pitt B., Stier C.T., Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003, 4:164-168.
13. Di Zhang A., Cat A.N., Soukaseum C., et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008, 52:1060-1067.
14. Christ M., Meyer C., Sippel K., et al. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 1995, 213:123-129.
15. Grossmann C., Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53-62.
16. Fuller P.J., Yao Y., Yang J., et al. Mechanism of ligand specificity of the mineralocorticoid receptor. J Endocrinol 2012, 213:15-24.
17. Briet M., Schiffrin E.L. Aldosterone effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010, 6:261-273.
18. Briet M., Schiffrin E.L. The role of aldosterone in metabolic syndrome. Curr Hypertens Rep 2011, 13:163-172.
19. Farman N., Rafestin-Oblin M.E. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001, 280:F181-F192.
20. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
21. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
22. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21. EMPHASIS-HF Study Group.
23. Corvol P., Michaud A., Menard J., et al. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975, 97:52-58.
24. Jeunemaitre X., Chatellier G., Kreft-Jais C., et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60:820-825.
25. Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005, 10:23-29.
26. Sica D.A., Flack J.M. Treatment considerations with aldosterone receptor antagonists. J Clin Hypertens (Greenwich) 2011, 13:65-69.
27. De Gasparo M., Joss U., Ramjoue H.P., et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650-656.
28. Garthwaite S.M., McMahon E.G. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004, 217:27-31.
29. Maron B.A., Leopold J.A. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010, 121:934-939.
30. McManus F., McInnes G.T., Connell J.M. Drug insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab 2008, 4:44-52.
31. Thompson D.F., Carter J.R. Drug-induced gynecomastia. Pharmacotherapy 1993, 13:37-45.
32. Struthers A.D., Unger T. Physiology of aldosterone and pharmacology of aldosterone blockers. Eur Heart J Suppl 2011, 13:B27-B30.
33. Struthers A., Krum H., Williams G.H. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008, 31:153-158.
34. Hermanson O., Glass C.K., Rosenfeld M.G. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 2002, 13:55-60.
35. Bledsoe R.K., Madauss K.P., Holt J.A., et al. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 2005, 280:31283-31293.
36. Yang J., Young M.J. The mineralocorticoid receptor and its coregulators. J Mol Endocrinol 2009, 43:53-64.
37. Fagart J., Wurtz J.M., Souque A., et al. Antagonism in the human mineralocorticoid receptor. EMBO J 1998, 17:3317-3325.
38. Hultman M.L., Krasnoperova N.V., Li S., et al. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005, 19:1460-1473.
39. Fagart J., Huyet J., Pinon G.M., et al. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005, 12:554-555.
40. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
41. Ruilope L.M. Current challenges in the clinical management of hypertension. Nat Rev Cardiol 2012, 9:267-275.
42. Calhoun D., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
43. Chapman N., Dobson J., Wilson S., et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
44. Schrier R.W. Use of diuretics in heart failure and cirrhosis. Semin Nephrol 2011, 1:503-512.
45. Rossi G.P., Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
46. Rossi G.P. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011, 7:485-495.
47. Colussi G., Catena C., Sechi L.A. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 2013, 31:3-15.
48. Catena C., Colussi G., Nadalini E., et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008, 168:80-85.
49. Sechi L.A., Colussi G., Di Fabio A., et al. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010, 23:1253-1260.
50. Sechi L.A., Di Fabio A., Bazzocchi M., et al. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009, 94:1191-1197.
51. Rossi G.P., Cesari M., Cuspidi C., et al. Response to effectiveness of adrenalectomy and aldosterone antagonists for long-term treatment of primary aldosteronism. Hypertension 2013, 62:e14.
52. Ori Y., Chagnac A., Korzets A., et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 2013, 28:1787-1793.
53. Karagiannis A., Tziomalos K., Papageorgiou A., et al. Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008, 9:509-515.
54. Parthasarathy H.K., Menard J., White W.B., et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011, 29:980-990.
55. Newton-Cheh C., Guo C.Y., Gona P., et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007, 49:846-856.
56. Meneton P., Galan P., Bertrais S., et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. J Hum Hypertens 2008, 22:550-558.
57. Clark D., Ahmed M.I., Calhoun D.A. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012, 28:318-325.
58. Weinberger M.H., Roniker B., Krause S.L., et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
59. Weinberger M.H., White W.B., Ruilope L.M., et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005, 150:426-433.
60. Lijnen P., Staessen J., Fagard R., et al. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982, 49:1561-1563.
61. Batterink J., Stabler S.N., Tejani A.M., et al. Spironolactone for hypertension. Cochrane Database Syst Rev 2010, 8:CD008169.
62. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
63. Lane D.A., Shah S., Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891-894.
64. Burgess E.D., Lacourcière Y., Ruilope-Urioste L.M., et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003, 25:2388-2404.
65. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148-1155.
66. White W.B., Duprez S., St Hillaire R., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021-1026.
67. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117-123.
68. Calhoun D.A., White W.B. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008, 2:462-468.
69. Bobrie G., Frank M., Azizi M., et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012, 30:1656-1664.
70. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981-2988.
71. Leopold J.A. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 2011, 124:e466-e468.
72. Zwadlo C., Bauersachs J. Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. Curr Opin Pharmacol 2013, 13:280-286.
73. Swedberg K., Eneroth P., Kjekshus J., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
74. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575.
75. Le Menuet D., Isnard R., Bichara M., et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001, 276:38911-38920.
76. Fraccarollo D., Berger S., Galuppo P., et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011, 123:400-408.
77. Lother A., Berger S., Gilsbach R., et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 2011, 57:746-754.
78. Bauersachs J. Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation. Eur J Clin Invest 2004, 34:649-652.
79. Kuster G.M., Kotlyar E., Rude M.K., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005, 111:420-427.
80. Sartorio C.L., Fraccarollo D., Galuppo P., et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007, 50:919-925.
81. Weir R.A., Tsorlalis I.K., Steedman T., et al. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur J Heart Fail 2011, 13:1305-1313.
82. McMurray J.J. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail 2011, 13:929-936.
83. Chan A.K., Sanderson J.E., Wang T., et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007, 50:591-596.
84. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
85. Rossignol P., Ménard J., Fay R., et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) Substudy. J Am Coll Cardiol 2011, 58:1958-1966.
86. Grandi A.M., Imperiale D., Santillo R., et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002, 40:647-652.
87. Boccanelli A., Mureddu G.F., Cacciatore G., et al. Antiremodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009, 11:68-76.
88. Di Pasquale P., Cannizzaro S., Scalzo S., et al. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. Am Heart J 2005, 150(919):e1-e8.
89. Beygui F., Labbé J.P., Cayla G., et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol 2013, 167:73-79.
90. Ezekowitz J.A., McAlister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009, 30:469-477.
91. Chatterjee S., Moeller C., Shah N., et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012, 125:817-825.
92. Tomaschitz A., Pilz S., Ritz E., et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010, 31:1237-1247.
93. Amano T., Matsubara T., Izawa H., et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006, 97:785-788.
94. Joffe H.V., Kwong R.Y., Gerhard-Herman M.D., et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552-2558.
95. Rita O.D., Hackam D.G., Spence J.D. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012, 28:706-711.
96. Vukusich A., Kunstmann S., Varela C., et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:1380-1387.
97. Keidar S., Hayek T., Kaplan M., et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41:955-963.
98. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212-2216.
99. Delpón E., Caballero R., Gómez R., et al. Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci 2005, 26:155-161.
100. Milliez P., Deangelis N., Rucker-Martin C., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005, 26:2193-2199.
101. Ouvrard-Pascaud A., Sainte-Marie Y., Benitah J.P., et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005, 111:3025-3033.
102. Gomez A.M., Rueda A., Sainte-Marie Y., et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009, 119:2179-2187.
103. Kimura S., Ito M., Tomita M., et al. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. Hypertens Res 2011, 34:584-591.
104. Shroff S.C., Ryu K., Martovitz N.L., et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006, 17:534-541.
105. Reil J.C., Hohl M., Selejan S., et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012, 33:2098-2108.
106. Swedberg K., Zannad F., McMurray J.J., et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012, 59:1598-1603.
107. Ramires F.J., Mansur A., Coelho O., et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000, 85:1207-1211.
108. Shah N.C., Pringle S.D., Donnan P.T., et al. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007, 25:2345-2351.
109. Bowling C.B., Pitt B., Ahmed M.I., et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010, 3:253-260.
110. Ahmed A., Zannad F., Love T.E., et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007, 28:1334-1343.
111. Alper A.B., Campbell R.C., Anker S.D., et al. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol 2009, 137:1-8.
112. Goyal A., Spertus J.A., Gosch K., et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012, 307:157-164.
113. Fallo F., Federspil G., Veglio F., et al. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep 2007, 9:106-111.
114. Yamaji M., Tsutamoto T., Kawahara C., et al. Effect of eplerenone versus spironolactone on cortisol and haemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 2010, 160:915-921.
115. Swaminathan K., Davies J., George J., et al. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008, 51:762-768.
116. Guder G., Bauersachs J., Frantz S., et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754-1761.
117. Bertocchio J.P., Warnock D.G., Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011, 79:1051-1060.
118. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int 2004, 66:1-9.
119. Schieppati A., Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int 2003, 64:1947-1955.
120. Volk M.J., Bomback A.S., Klemmer P.J. Mineralocorticoid receptor blockade in chronic kidney disease. Curr Hypertens Rep 2011, 13:282-288.
121. Quinkler M., Zehnder D., Eardley K.S., et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005, 112:1435-1443.
122. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
123. Bomback A.S., Kshirsagar A.V., Amamoo M.A., et al. Change in proteinuria after adding aldosterone blockers to ace inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211.
124. Navaneethan S.D., Nigwekar S.U., Sehgal A.R., et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:542-551.
125. Bianchi S., Bigazzi R., Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116-2123.
126. Sato A., Hayashi K., Naruse M., et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
127. Rossing K., Schjoedt K.J., Smidt U.M., et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005, 28:2106-2112.
128. Rossignol P., Cleland J.G., Bhandari S., et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study. Circulation 2012, 125:271-279.
129. Sungaila I., Bartle W.R., Walker S.E., et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992, 102:1680-1685.
130. Kolkhof P., Borden S.A. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012, 350:310-317.
131. Gulmez S.E., Lassen A.T., Aalykke C., et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008, 66:294-299.
132. Pitt B., Bakris G., Ruilope L.M., et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008, 118:1643-1650.
133. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
134. Goland S., Naugolny V., Korbut Z., et al. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic. Eur J Intern Med 2011, 22:424-427.
135. Phillips C.O., Kashani A., Ko D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007, 167:1930-1936.
136. Cavallari L.H., Groo V.L., Viana M.A., et al. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy 2010, 30:1-9.
137. Pitt B., Anker S.D., Bushinsky D.A., et al. PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011, 32:820-828.
138. Raebel M.A., McClure D.L., Chan K.A., et al. Laboratoryevaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?. Ann Pharmacother 2007, 41:193-200.
139. Eschalier R., McMurray J.J., Swedberg K., et al. EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013, 62:1585-1593.
140. Menard J., Gonzalez M.F., Guyene T.T., et al. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006, 24:1147-1155.
141. Geller D.S., Farhi A., Pinkerton N., et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
142. Arhancet G.B., Woodard S.S., Dietz J.D., et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 2010, 53:4300-4304.
143. Dietz J.D., Du S., Bolten C.W., et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008, 51:742-748.
144. Matsui T., Takeuchi M., Yamagishi S., et al. Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 2010, 396:566-570.
145. Kosaka H., Hirayama K., Yoda N., et al. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 2010, 635:49-55.
146. Arhancet G.B., Woodard S.S., Iyanar K., et al. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J Med Chem 2010, 53:5970-5978.
147. Fagart J., Hillisch A., Huyet J., et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010, 285:29932-29940.
148. Bärfacker L., Kuhl A., Hillisch A., et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem 2012, 7:1385-1403.
149. Meyers M.J., Arhancet G.B., Hockerman S.L., et al. Discovery of (3S, 3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3, 3a, 4, 5-tetrahydro-2H-b enzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010, 53:5979-6002.
150. + excretion activity. J Pharmacol Sci 2011, 115:346-353.
151. Delbeck M., Kretschmer A., Kast R., et al. Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure [abstract]. Eur Heart J 2012, 33(Suppl):772.
152. Albrecht-Kuepper B., Kretschmer A., Kast R., et al. Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure [abstract]. Eur Heart J 2012, 32(Suppl):7.
153. Pitt B., Kober L., Ponikowski P., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013, 34:2453-2463.
154. Azizi M., Amar L., Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant 2013, 28:36-43.
155. Fiebeler A., Nussberger J., Shagdarsuren E., et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.
156. Lombès M., Alfaidy N., Eugene E., et al. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175-182.
157. Amar L., Azizi M., Menard J., et al. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens 2013, 31:624-629.
158. Lea W.B., Kwak E.S., Luther J.M., et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009, 75:936-944.
159. Mulder P., Mellin V., Favre J., et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008, 29:2171-2179.
160. Gamliel-Lazarovich A., Gantman A., Coleman R., et al. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens 2010, 28:1900-1907.
161. Menard J., Watson C., Rebello S., et al. Hormonal and electrolyte responses to the aldosterone synthase inhibitor lCI699 in sodium depleted healthy subjects. J Am Coll Cardiol 2010, 55:A61.
162. Schumacher C.D., Steele R.E., Brunner H.R. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens 2013, 31:2085-2093.
163. Calhoun D.A., White W.B., Krum H., et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011, 124:1945-1955.
164. Andersen K., Hartman D., Peppard T., et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 2012, 14:580-587.
165. Karns A.D., Bral J.M., Hartman D., et al. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2013, 15:186-192.
166. Amar L., Azizi M., Menard J., et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010, 56:831-838.
167. Zimmer C., Hafner M., Zender M., et al. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg Med Chem Lett 2011, 21:186-190.
168. Imagawa K., Okayama S., Takaoka M., et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006, 47:133-138.
169. 2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008, 584:424-434.
170. Isaka T., Ikeda K., Takada Y., et al. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2009, 605:49-52.
171. Robertson S., MacKenzie S.M., Alvarez-Madrazo S., et al. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension 2013, 62:572-578.
172. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp Opin Pharmacother. 2014;15:605-21.
173. Ernst M.E., Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009, 361:2153-2164.
174. Viswanathan V., Mohan V., Subramani P., et al. Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes. Clin J Am Soc Nephrol 2013, 8:225-232.
175. Baker E.H., Duggal A., Dong Y., et al. Amiloride, a specific drug for hypertension in black people with T594M variant?. Hypertension 2002, 40:13-17.
176. Rayner B.L., Trinder Y.A., Baines D., et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006, 19:208-213.
177. Farquharson C.A., Struthers A.D. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 2002, 88:475-480.